Andrew Menzies-Gow

Andrew Menzies-Gow

Auto-generated profile, based on publicly available information

Andrew Menzies-Gow

AstraZeneca Cambridge UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
AMAndrew Menzies-Gow
Andrew Menzies-Gow
MBMona Bafadhel
Mona Bafadhel
WBWilliam W. Busse
William W. Busse
TCThomas B. Casale
Thomas B. Casale
JKJanwillem W.H. Kocks
Janwillem W.H. Kocks
CAChristopher S. Ambrose
Christopher S. Ambrose
With novel therapies in development, there is an opportunity to consider asthma remission as a treatment goal. In this Rostrum, we present a generalized framework for clinical and complete remission in asthma, on and off treatment, developed on the basis of medical literature and expert consensus. A modified Delphi survey approach was used to ascertain expert consensus on core components of asthma remission as a treatment target. Phase 1 identified other chronic inflammatory diseases with remission definitions. Phase 2 evaluated components of those definitions as well as published definitions of spontaneous asthma remission. Phase 3 evaluated a remission framework created using consensus findings. Clinical remission comprised 12 or more months with (1) absence of significant symptoms by validated instrument, (2) lung function optimization/stabilization, (3) patient/provider agreement regarding remission, and (4) no use of systemic corticosteroids. Complete remission was defined as clinical remission plus objective resolution of asthma-related inflammation and, if appropriate, negative bronchial hyperresponsiveness. Remission off treatment required no asthma treatment for 12 or more months. The proposed framework is a first step toward developing asthma remission as a treatment target and should be refined through future research, patient input, and clinical study.

27 January 2016 in Thorax
Verified
Journal Article
Open access
PDF file
JSJoan Sweeney
Joan Sweeney
CPChris C Patterson
Chris C Patterson
AMAndrew Menzies-Gow
Andrew Menzies-Gow
RNRob M Niven
Rob M Niven
AMAdel H Mansur
Adel H Mansur
LHLiam G Heaney
Liam G Heaney
Objective To determine the prevalence of systemic corticosteroid-induced morbidity in severe asthma. Design Cross-sectional observational study. Setting The primary care Optimum Patient Care Research Database and the British Thoracic Society Difficult Asthma Registry. Participants Optimum Patient Care Research Database (7195 subjects in three age- and gender-matched groups)—severe asthma (Global Initiative for Asthma (GINA) treatment step 5 with four or more prescriptions/year of oral corticosteroids, n=808), mild/moderate asthma (GINA treatment step 2/3, n=3975) and non-asthma controls (n=2412). 770 subjects with severe asthma from the British Thoracic Society Difficult Asthma Registry (442 receiving daily oral corticosteroids to maintain disease control). Main outcome measures Prevalence rates of morbidities associated with systemic steroid exposure were evaluated and reported separately for each group. Results 748/808 (93%) subjects with severe asthma had one or more condition linked to systemic corticosteroid exposure (mild/moderate asthma 3109/3975 (78%), non-asthma controls 1548/2412 (64%); p<0.001 for severe asthma versus non-asthma controls). Compared with mild/moderate asthma, morbidity rates for severe asthma were significantly higher for conditions associated with systemic steroid exposure (type II diabetes 10% vs 7%, OR=1.46 (95% CI 1.11 to 1.91), p<0.01; osteoporosis 16% vs 4%, OR=5.23, (95% CI 3.97 to 6.89), p<0.001; dyspeptic disorders (including gastric/duodenal ulceration) 65% vs 34%, OR=3.99, (95% CI 3.37 to 4.72), p<0.001; cataracts 9% vs 5%, OR=1.89, (95% CI 1.39 to 2.56), p<0.001). In the British Thoracic Society Difficult Asthma Registry similar prevalence rates were found, although, additionally, high rates of osteopenia (35%) and obstructive sleep apnoea (11%) were identified. Conclusions Oral corticosteroid-related adverse events are common in severe asthma. New treatments which reduce exposure to oral corticosteroids may reduce the prevalence of these conditions and this should be considered in cost-effectiveness analyses of these new treatments.

1 June 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Open access
DLDiane Lefaudeux
Diane Lefaudeux
BMBertrand De Meulder
Bertrand De Meulder
MLMatthew J. Loza
Matthew J. Loza
NPNancy Peffer
Nancy Peffer
ARAnthony Rowe
Anthony Rowe
KZKoos Zwinderman
Koos Zwinderman
Asthma is a heterogeneous disease in which there is a differential response to asthma treatments. This heterogeneity needs to be evaluated so that a personalized management approach can be provided. We stratified patients with moderate-to-severe asthma based on clinicophysiologic parameters and performed an omics analysis of sputum. Partition-around-medoids clustering was applied to a training set of 266 asthmatic participants from the European Unbiased Biomarkers for the Prediction of Respiratory Diseases Outcomes (U-BIOPRED) adult cohort using 8 prespecified clinic-physiologic variables. This was repeated in a separate validation set of 152 asthmatic patients. The clusters were compared based on sputum proteomics and transcriptomics data. Four reproducible and stable clusters of asthmatic patients were identified. The training set cluster T1 consists of patients with well-controlled moderate-to-severe asthma, whereas cluster T2 is a group of patients with late-onset severe asthma with a history of smoking and chronic airflow obstruction. Cluster T3 is similar to cluster T2 in terms of chronic airflow obstruction but is composed of nonsmokers. Cluster T4 is predominantly composed of obese female patients with uncontrolled severe asthma with increased exacerbations but with normal lung function. The validation set exhibited similar clusters, demonstrating reproducibility of the classification. There were significant differences in sputum proteomics and transcriptomics between the clusters. The severe asthma clusters (T2, T3, and T4) had higher sputum eosinophilia than cluster T1, with no differences in sputum neutrophil counts and exhaled nitric oxide and serum IgE levels. Clustering based on clinicophysiologic parameters yielded 4 stable and reproducible clusters that associate with different pathobiological pathways.

22 March 2017 in Respirology
Verified
Journal Article
Open access
PDF file
CPCeleste Porsbjerg
Celeste Porsbjerg
AMAndrew Menzies‐Gow
Andrew Menzies‐Gow
Patients with severe asthma represent a minority of the total asthma population, but carry a majority of the morbidity and healthcare costs. Achieving better asthma control in this group of patients is therefore of key importance. Systematic assessment of patients with possible severe asthma to identify treatment barriers and triggers of asthma symptoms, including co‐morbidities, improves asthma control and reduces healthcare costs and is recommended by international guidelines on management of severe asthma.This review provides the clinician with an overview of the prevalence and clinical impact of the most common co‐morbidities in severe asthma, including chronic rhinosinusitis, nasal polyposis, allergic rhinitis, dysfunctional breathing, vocal cord dysfunction, anxiety and depression, obesity, obstructive sleep apnoea syndrome (OSAS), gastroesophageal reflux disease (GERD), bronchiectasis, allergic bronchopulmonary aspergillosis (ABPA) and eosinophilic granulomatous with polyangiitis (EGPA). Furthermore, the review offers a summary of recommended diagnostic and management approaches for each co‐morbidity. Finally, the review links co‐morbid conditions to specific phenotypes of severe asthma, in order to guide the clinician on which co‐morbidities to look for in specific patients.

1 January 2022 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
AMAndrew Menzies-Gow
Andrew Menzies-Gow
MGMark Gurnell
Mark Gurnell
LHLiam G Heaney
Liam G Heaney
JCJonathan Corren
Jonathan Corren
EBElisabeth H Bel
Elisabeth H Bel
EGEsther Garcia Gil
Esther Garcia Gil

10 June 2014 in Thorax
Verified
Journal Article
Open access
PDF file
SOStephen O’Neill
Stephen O’Neill
JSJoan Sweeney
Joan Sweeney
CPChris C Patterson
Chris C Patterson
AMAndrew Menzies-Gow
Andrew Menzies-Gow
RNRob Niven
Rob Niven
ONOn Behalf Of The British Thoracic Society Difficult Asthma Network
On Behalf Of The British Thoracic Society Difficult Asthma Network
Severe refractory asthma poses a substantial burden in terms of healthcare costs but relatively little is known about the factors which drive these costs. This study uses data from the British Thoracic Society Difficult Asthma Registry (n=596) to estimate direct healthcare treatment costs from an National Health Service perspective and examines factors that explain variations in costs. Annual mean treatment costs among severe refractory asthma patients were £2912 (SD £2212) to £4217 (SD £2449). Significant predictors of costs were FEV1% predicted, location of care, maintenance oral corticosteroid treatment and body mass index. Treating individuals with severe refractory asthma presents a substantial cost to the health service.